A Phase 1, Open-Label, Single and Multiple Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)
Latest Information Update: 13 Mar 2025
At a glance
- Drugs Ulviprubart (Primary)
- Indications Inclusion body myositis
- Focus Adverse reactions; First in man
- Sponsors Abcuro
Most Recent Events
- 11 Mar 2025 According to an Abcuro media release, Company will present safety, pharmacokinetic, and pharmacodynamic data from this phase 1 study at the American Academy of Neurology (AAN) Annual Meeting, taking place April 5-9, 2025, in San Diego, California.
- 20 Feb 2025 Status changed from active, no longer recruiting to completed.
- 04 Jun 2024 Planned End Date changed from 1 Mar 2024 to 1 Aug 2025.